A Randomized Study of Interferon α-2b Versus No Treatment as Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Patients With Relapsed Lymphoma

Autor: André Bosly, Hans Hagberg, Bertrand Coiffier, John J. Radford, Armando López-Guillermo, Philippe Colombat, Andrea Rossi, Marek Trneny, Christian Gisselbrecht, Harald H. Holte, Catherine Sebban, Dominique Bron, Fernando Leal da Costa, Andrew A. Grigg

Publikováno v: The Oncologist. 18:1189-1189

Background. Patients with lymphoma who have experienced a first relapse or progression and have disease deemed sensitive to salvage chemotherapy nevertheless have a high likelihood of having a second relapse. To decrease the likelihood of a second re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f12668c47627e0ebd11f6f608b129c30
https://doi.org/10.1634/theoncologist.2013-0223

Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma.

Autor: Bai B; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Clinical Molecular Biology (EpiGen),, Akershus University Hospital, Lørenskog, Norway., Wise JF; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Massachusetts General Hospital Cancer Center and Department of Pathology, Harvard Medical School, Charlestown, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Vodák D; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Nakken S; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Centre for Bioinformatics, University of Oslo, Oslo, Norway., Sharma A; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Blaker YN; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Brodtkorb M; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Division for Cancer Medicine, Oslo University Hospital, Oslo, Norway., Hilden V; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Trøen G; Department of Pathology, Oslo University Hospital, Oslo, Norway., Ren W; Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden., Lorenz S; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Genomics Core Facility, Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Lawrence MS; Massachusetts General Hospital Cancer Center and Department of Pathology, Harvard Medical School, Charlestown, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Myklebost O; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Department for Clinical Science, University of Bergen, Bergen, Norway., Kimby E; Unit for Hematology and Department of Medicine at Karolinska Institutet, Huddinge, Stockholm, Sweden., Pan-Hammarström Q; Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden., Steen CB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Meza-Zepeda LA; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Genomics Core Facility, Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Beiske K; Department of Pathology, Oslo University Hospital, Oslo, Norway., Smeland EB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Hovig E; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Centre for Bioinformatics, University of Oslo, Oslo, Norway., Lingjærde OC; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Informatics, University of Oslo, Oslo, Norway.; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Holte H; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. hhe@ous-hf.no.; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway. hhe@ous-hf.no.; Department of Oncology, Division for Cancer Medicine, Oslo University Hospital, Oslo, Norway. hhe@ous-hf.no., Myklebust JH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. j.h.myklebust@medisin.uio.no.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. j.h.myklebust@medisin.uio.no.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway. j.h.myklebust@medisin.uio.no.

Publikováno v: Blood cancer journal [Blood Cancer J] 2024 Aug 27; Vol. 14 (1), pp. 147. Date of Electronic Publication: 2024 Aug 27.

MetaGate: Interactive analysis of high-dimensional cytometry data with metadata integration.

Autor: Ask EH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; The Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Tschan-Plessl A; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Division of Hematology, University Hospital Basel, Basel, Switzerland., Hoel HJ; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Kolstad A; Department of Oncology, Innlandet Hospital Trust Division Gjøvik, Lillehammer, Norway., Holte H; Department of Oncology, Oslo University Hospital, Oslo, Norway.; K.G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Malmberg KJ; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; The Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.

Publikováno v: Patterns (New York, N.Y.) [Patterns (N Y)] 2024 May 13; Vol. 5 (7), pp. 100989. Date of Electronic Publication: 2024 May 13 (Print Publication: 2024).

Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma.

Autor: Spasevska I; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Sharma A; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Steen CB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.; Division of Oncology, Stanford University School of Medicine, Stanford, CA., Josefsson SE; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Blaker YN; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Kolstad A; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Department of Oncology, Innlandet Hospital Trust, Lillehammer, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Rustad EH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Meyer S; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Isaksen K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Chellappa S; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Kushekhar K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Beiske K; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway., Førsund MS; Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway., Spetalen S; Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway., Holte H; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Østenstad B; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Brodtkorb M; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Kimby E; Department of Hematology, Karolinska Institute, Stockholm, Sweden., Olweus J; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Norway., Taskén K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Newman AM; Division of Oncology, Stanford University School of Medicine, Stanford, CA.; Divisions of Hematology & Oncology, Department of Medicine, Stanford University, Stanford, CA., Lorenz S; Department of Core Facilities, Geonomics Core Facility, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Smeland EB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Alizadeh AA; Division of Oncology, Stanford University School of Medicine, Stanford, CA.; Divisions of Hematology & Oncology, Department of Medicine, Stanford University, Stanford, CA., Huse K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Myklebust JH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.

Publikováno v: Blood advances [Blood Adv] 2023 Dec 12; Vol. 7 (23), pp. 7216-7230.

Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas.

Autor: Leivonen SK; Applied Tumor Genomics Research Program, Medical Faculty, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki., Friman T; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki., Autio M; Applied Tumor Genomics Research Program, Medical Faculty, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki., Vaittinen S; Department of Pathology, Turku University Hospital, University of Turku, Turku., Jensen AW; Department of Hematology, Aarhus University Hospital, Aarhus., D'Amore F; Department of Hematology, Aarhus University Hospital, Aarhus., Hamilton-Dutoit SJ; Institute of Pathology, Aarhus University Hospital, Aarhus., Holte H; Department of Oncology, Oslo University Hospital, Oslo, Norway., Beiske K; Department of Pathology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Kovanen PE; Department of Pathology, University of Helsinki, and HUSLAB, Helsinki University Hospital, Helsinki., Räty R; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki., Leppä S; Applied Tumor Genomics Research Program, Medical Faculty, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki. sirpa.leppa@helsinki.fi.

Publikováno v: Haematologica [Haematologica] 2023 Nov 01; Vol. 108 (11), pp. 3044-3057. Date of Electronic Publication: 2023 Nov 01.